The CRI Cancer Immunotherapy Consortium (CIC) contributes to the creation of white papers, response documents, and peer-reviewed publications advancing novel outcomes from workshops that seek practical solutions to today's challenges in cancer immunotherapy development.
Publications prior to 2010 are credited to the Cancer Vaccine Consortium, the former name of the Cancer Immunotherapy Consortium.
A browser plugin may be required for the PDF file found this page.
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
Terence Friedlander, M.D., answers questions about immunotherapy for bladder cancer from the 2020 CRI Virtual Immunotherapy Patient Summit.
Dr. Elizabeth Jaffee answers questions on immunotherapy for pancreatic cancer from the 2020 CRI Virtual Immunotherapy Patient Summit.